Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.

ABSTRACT:

Background

The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors represented a paradigm shift in the treatment of ovarian cancer. Genomic data from patients with high-grade ovarian cancer in six phase II/III trials involving the PARP inhibitor olaparib were analyzed to better understand patterns and potential causes of genomic instability.

Patients and methods

Homologous recombination deficiency (HRD) was assessed in 2147 tumor samples from SOLO1, PAOLA-1, Study 19, SOLO2, OPINION, and LIGHT using next-generation sequencing technology. Genomic instability scores (GIS) were assessed in BRCA1 and/or BRCA2 (BRCA)-mutated (BRCAm), non-BRCA homologous recombination repair-mutated (non-BRCA HRRm), and non-HRRm tumors.

Results

BRCAm was identified in 1021/2147 (4

SUBMITTER: Barnicle A 

PROVIDER: S-EPMC11657106 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature